On this page you can find clinical trials that Ipsen has sponsored and clinical trials that were acquired by Ipsen. You can use the drop-down lists below to find clinical trials by condition, status, phase and country.
Completed clinical trials may also have results available. If so, a simple summary of the overall results can be found on the lay summaries page.
You may also find a scientific summary of the results on the US and EU Clinical Trial Registries.
The ‘status’ of participant recruitment is defined as follows:
- Not yet recruiting – recruitment has not started yet
- Recruiting – recruitment is open
- Enrolling by invitation – recruitment is open to a particular population who are invited to participate.
- Active, not recruiting – recruitment is closed, participants are still ongoing in the clinical trial;
- Terminated – the study stopped early.
- Completed – the study ended.
Last Data Refreshed @ 24-Apr-2024 03:11:49 UTC
Filters
Condition
Status
Phase
Country
Showing : 1 – 5 of 152 clinical trials
Chronic Migraine
Dysport
United States of America (the)
Canada
Georgia
Recruiting
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Chronic Migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache days. Migraines are caused by a series of events which cause the brain to get stimulated/activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers. The study will consist of 2 or 3 periods: 1. A ’screening period’ of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit. 2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders. The injections will contain either Dose A or Dose B of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits. 3. A second, extension Treatment Phase of 24 weeks. SMD form protocol master data–5- INT / Version 1 In the second Treatment Phase, all participants will get Dysport® (Dose A or Dose B). There will be 3 in person visits and 4 remote visits. Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months).
Episodic Migraine
Dysport
Georgia
Canada
United States of America (the)
Recruiting
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing episodic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches. Migraines are caused by a series of events which cause the brain to get stimulated/activated, which results in the release of chemicals that cause pain. Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers. The study will consist of 2 or 3 periods: 1. A ’screening period’ of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit. 2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders. The injections will contain either Dose A or Dose B of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied). Participants will make 4 visits to the clinic in person and have 4 remote (online) visits. 3. A second, extension Treatment Phase of 24 weeks. In the second Treatment Phase, all participants will get Dysport® (Dose A or Dose B). There will be 3 in person visits and 4 remote visits. Participants will need to complete an e-diary and questionnaires throughout the study. Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded. The total study duration for a participant will be up to 60 weeks (approx. 14 months).
Primary Sclerosing Cholangitis
elafibranor
Germany
Canada
Italy
United States of America (the)
United Kingdom of Great Britain and Northern Ireland (the)
Spain
Portugal
Recruiting
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis.
This study will evaluate the effects of elafibranor (the study drug) in participants with Primary Sclerosing Cholangitis (PSC). PSC is a rare disease of the liver that leads to injury and destruction of bile ducts. Damage to bile ducts leads to buildup of bile in the liver, which then causes further damage, and leads to disease progression. This study will compare elafibranor to a placebo, a dummy treatment. The main objective of the trial will be to study the safety and side effects of the study drug. The trial will also study the study drug’s effects on blood tests and other tests related to PSC disease activity.
Primary Biliary Cholangitis (PBC)
elafibranor
Spain
Romania
United States of America (the)
Korea (the Republic of)
Czechia
Recruiting
A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC). Participants will also have inadequate response or intolerance to ursodeoxycholic acid (UDCA). UDCA is a medication used in the management and treatment of PBC. PBC is a disease that progresses slowly. It causes damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage. The liver damage in PBC may lead to scarring (cirrhosis). PBC may also be associated with multiple symptoms. Many people with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done. This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment). Each participant will be in the study for about 7 years. The main aim of this study is to determine if elafibranor is better than placebo in preventing adverse (bad) clinical outcomes including progression of disease leading to liver transplant or death. This study will also study the safety of long-term treatment with elafibranor, as well as the impact on symptoms such as itching and tiredness.
Fibrodysplasia Ossificans Progressiva
fidrisertib
United States of America (the)
United Kingdom of Great Britain and Northern Ireland (the)
Sweden
Spain
Portugal
Mexico
Belgium
Canada
China
France
Korea (the Republic of)
Japan
Netherlands (Kingdom of the)
Italy
Australia
Argentina
Recruiting
A study to assess the effectiveness and safety of 2 dosage regimens of oral fidrisertib (IPN60130) for the treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone normally does not exist, known as Heterotopic Ossification (HO). It is often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to abnormal stiffening and immobility (ankyloses) of major joints with cumulative and irreversible loss of movement and disability. This study will evaluate the efficacy of 2 dosing regimens of IPN60130 in inhibiting new HO volume compared with placebo (a dummy treatment) in adult and paediatric participants with FOP. It will be assessed by a scan (provides internal images of the body) called low dose Whole Body Computed Tomography (WBCT), excluding head. Adults and participants 15 years of age or older are also eligible for a sub study to evaluate HO lesions assessed by another type of scan, Fluorine-18-labelled natrium fluoride Positron Emission Tomography-Computed Tomography ([18F]NaF PETCT ). This will be a 3-part study: Part A will be a 12-month, 3-arm, parallel-group, randomised, double-blind, placebo-controlled period during which participants will be randomised to low or high weight-based IPN60130 dosage arms or placebo, Part B will be a 12-month, 2-arm, randomised, double-blind period during which participants will receive high or low weight-based daily dosages of IPN60130. Participants completing Part A will enter Part B: placebo recipients from Part A will be randomised to one of the IPN60130 dosage arms with a 1:1 ratio, whereas participants receiving IPN60130 will remain in their respective dosage arms. Part C will be a 36-month, extension period. All participants completing Part B will continue in the same IPN60130 treatment arm for additional 36-month treatment in Part C.